Cue Biopharma names Dominic Borie chief medical officer, head of R&D
CUE•Pipeline timing remains in focus
Management shift comes as Cue targets Phase 2 chronic spontaneous urticaria data for CUE-221 by the end of Q3 2026.
Cue also plans a Phase 1 start for CUE-401, a bifunctional IL-2 and TGF-β molecule, by the end of Q4.
Cue Biopharma names new chief medical officer and head of R&D
Cue Biopharma named Dominic Borie as chief medical officer and head of research and development, reporting to CEO Shao-Lee Lin.
Borie was strategic adviser to Kyverna’s CEO and board, previously serving as president of R&D and founding CEO. He previously held senior roles at Horizon Therapeutics, Genentech, Amgen and Roche; earlier he led Stanford’s Transplantation Immunology Laboratory.
